January – December 2022

Year-end report

alzinova

We will make it possible for Alzheimer's patients to live an independent and active life

Summary of the period October - December 2022

Highlights - fourth quarter

Interim data from the phase 1b study
- Show positive safety data and immunogenic response

Phase 1b study fully enrolled
- All patients now enrolled in phase 1b study

Unique binding profile of ALZ-201 antibody
- "Best in class" potential, binds to oligomers to a greater extent compared to other antibodies

Key figures from the period

Three months, October – December 2022

- Net sales amounted to SEK 0 (SEK 0).
- Result after financial items amounted to SEK -4,734,807 (SEK -2,455,624).
- Number of outstanding shares 32,419,034 (15,775,724).
- Average number of shares during the period 32,419,034 (15,775,724).
- Earnings per share before dilution amounted to SEK -0.15 (SEK -0.16).

Twelve months, January – December 2022

- Net sales amounted to SEK 0 (SEK 0).
- Result after financial items amounted to SEK -13,087,849 (SEK -7,552,006).
- Number of shares outstanding 32,419,034 (15,775,724).
- Average number of shares during the period 24,364,688 (15,775,724).
- Earnings per share before dilution amounted to SEK -0.40 (SEK -0.48).
- Cash and cash equivalents at the end of the period amounted to SEK 32.0 million (SEK 28.8 million).
- Equity ratio amounted to 94.5% (96.5%).
- The board proposes that no dividends are paid for 2022.

Equity ratio: Total equity divided by total capital.
Amounts in brackets: Corresponding period in previous year.
"the Company" or **"Alzinova"** refers to Alzinova AB with corporate identity number: 556861-8168.

Events during the fourth quarter 2022

- On October 4, Alzinova announced that CSO Anders Sandberg was interviewed in Biostock where he shared his scientific reflections on the latest developments in the industry.
- Alzinova announced on October 10 that the Company would present at both Swedish and international investor meetings and partnering meetings during the autumn.
- On November 23, Alzinova announced that the Company will change Certified Advisor to Redeye AB as of December 1, 2022.
- On November 29, the Company announced that CSO Anders Sandberg gave a presentation about the ALZ-201 antibody's unique binding profile at the major international Alzheimer's conference Clinical Trials in Alzheimer's Disease (CTAD).
- On December 12, Alzinova announced that the Company has received a new positive safety review and interim data from the ongoing phase 1b study with the vaccine candidate ALZ-101. The result indicates an immunological response, i.e. antibodies have been formed, and the study is proceeding as planned.
- On December 19, Alzinova announced that the phase 1b trial had been fully recruited and that the target of completing recruitment by the end of the year had been achieved.

Events after the end of the fourth quarter 2022

- Alzinova announced on 3 January 2023 that a scientific article has been published in the prestigious journal Alzheimer's Research & Therapy with preclinical results demonstrating that the ALZ-201 antibody has specificity for the toxic oligomers thought to be the cause of Alzheimer's disease. Furthermore, the research shows that ALZ-201 has the potential to be "best-in-class" in the clinic, with good efficacy and a more favourable side effect profile than other antibodies.
- Alzinova announced on January 24 that Sebastian Hansson has been recruited to the newly created role of Business Development Director.



A word from the CEO

2022 was a year of many successes, with several important milestones achieved. Enrolment in the ongoing clinical trial was completed on schedule in December and we now look forward to study results in the second half of 2023. In addition, the past year has seen interesting and important research results that have strengthened the Company's strategy - to develop effective and safe amyloid-beta treatments for Alzheimer's disease.

ALZ-101 vaccine - favourable safety profile and indications of immune response

During the year, the independent Data Safety Monitoring Board has continuously reviewed safety data from our ongoing phase 1b clinical trial. I am very pleased that the study shows continued good safety and tolerability of the treatment, which is also the goal of the first clinical trial. We also conducted a first interim analysis of blinded efficacy and safety data from patients in the study in December. The information we received from this early interim analysis was very positive, again showing that the treatment is safe and well tolerated. In addition, we received data indicating an immunological response, i.e. antibodies have been formed and one could say that this is a sign that ALZ-101 is doing its job!

Furthermore, we ended the year by announcing that the study is fully recruited. The fact that the last patient started treatment in December was a very important milestone for the study to continue as planned where we look forward to further interim safety and immunological data in the spring and top-line data in the second half of 2023. During the year we have also demonstrated that larger volumes of our vaccine candidate ALZ-101 can be produced. Taken together, this lays the foundation for the next step in the clinical development of ALZ-101 i.e. phase 2 trials. In parallel, we are preparing for interactions with regulatory authorities. With the progress we have made during the year, it strengthens our position in the market and it increases the interest of other companies to partner with us.

Unique binding profile - "best in class" potential

This autumn, the unique binding profile of our antibody ALZ-201 was presented at the major international Alzheimer's congress CTAD. These data have attracted great interest, as have the research results recently published on this antibody. In a comparative analysis between the oligomer-specific antibody ALZ-201 (which we developed from the vaccine ALZ-101) and copies of the antibodies lecanemab, aducanumab, and gantenerumab, it was found that ALZ-201 binds to a greater extent to the toxic accumulations of amyloid-beta, so-called oligomers.

We are convinced that an oligomer-specific treatment with an antibody such as ALZ-201 or the ALZ-101 vaccine with "best in class" potential has the potential to provide significantly better efficacy with a more favourable side effect profile than observed for other therapies. In addition, our ALZ-101 vaccine can be administered much less frequently than other drug candidates in development for the treatment of Alzheimer's. This also contributes to better health economics, as a more effective and simpler treatment is more convenient and less burdensome for the patient and requires less from both the patient and society.

Alzinova's strategy strengthened - increased interest in the Company

In the autumn, data were presented from the large phase 3 study in Alzheimer's patients conducted by the Japanese pharmaceutical company Eisai with the monoclonal antibody lecanemab - developed by BioArctic. We see this as positive for both the Alzheimer's field and Alzinova as it re-enforces our strategy to develop novel, effective and safe amyloid-beta treatments for Alzheimer's disease. This of course also contributes to an increased interest in Alzinova and our unique portfolio of drug candidates that have strong potential to be "best in class", which we are very excited about.

Strengthened organisation and financial position

Alzinova has also strengthened the organisation through recruitments in clinical development and regulatory affairs as part of the preparatory work for the phase 2 clinical trial. We are focusing on business development and building up the area to position the Company and intensify partnering activities. As part of this work, we have recruited a Business Development Director. During the autumn, we participated in BIO-Europe where we met with potential licensees of our programmes. We noted strong interest in our pipeline and the upcoming milestones from our ongoing clinical trial.

We strengthened our financial position through the rights issue that was completed in the second quarter of 2022. We are very grateful for the interest in the Company and I would like to thank both our existing shareholders for their confidence and all interested parties who have chosen to invest in Alzinova. Through this financing and with the upcoming warrants in April 2023, we expect to have funding to complete the ongoing clinical trial and preparations for phase 2.

Alzinova develops next generation Alzheimer's drug

Over the past year, I have seen first-hand how Alzheimer's breaks people down and how it affects the lives of loved ones. I am deeply committed and passionate about my work to develop medicines for this terrible disease. I am proud to lead this innovative Company with my amazing Alzinova team, partners and board of directors who are all helping to make the development of the next generation of Alzheimer's drugs possible. We now look forward to continuing to accelerate the Company's progress and delivering a strong 2023.

Kristina Torfgård,
Alzinova AB

> **We are developing the next generation of Alzheimer's drugs with "best in class" potential**



About Alzinova

Alzinova AB is a Swedish biopharmaceutical Company specializing in the treatment of Alzheimer's disease. The Company's proprietary AβCC peptide technology™ enables the development of disease-modifying treatments that, with high precision, target the toxic accumulations of the peptide amyloid beta, so-called oligomers, which are central to the onset and progression of the disease. Using this technology, we can develop effective treatments which at the same time have a favourable safety profile with a lower risk of side effects. Promising preclinical results have been obtained following completion of a study on brain extracts from deceased Alzheimer's patients. The study confirms that Alzinova's unique method for specifically targeting and neutralizing toxic oligomers is effective.

Alzinova's focus is the development of a vaccine that specifically targets and neutralizes the toxic oligomers. The vaccine is developed as a long-acting drug for the treatment and prevention of Alzheimer's disease. The drug candidate ALZ-101 is in clinical development and a phase 1b study with Alzheimer's patients was initiated in the third quarter of 2021 and was fully recruited in december 2022. Top-line data is expected to be presented in the second half of 2023.

Based on the same technology, the Company is also developing the antibody, ALZ-201, which is currently in the preclinical development phase. The project portfolio for the development of disease-modifying treatments is broadened by the Company by preparing the antibody so that it can also be taken into the clinical phase. Alzinova was founded by researchers who worked at the MIVAC research center at the University of Gothenburg and by GU Ventures AB.

Alzinova's unique solution

- Targeted treatment that specifically targets and neutralizes the toxic peptides (so-called oligomers) that are central to the onset and development of Alzheimer's disease
- Vaccine that stimulates the body to produce its own antibodies against oligomers
- Antibody that neutralizes the peptides and can be used as is or as a complement to the vaccine
- Fast, effective and uncomplicated vaccination without long and expensive hospital stays
- Specific treatment that is likely to have good efficacy and reduces the risk of serious side effects
- Can start treatment early in the disease to prevent progression

Other actors

- Are developing treatments that target larger accumulations of amyloid-beta, so-called plaques in the brain, which are believed to contain both toxic and harmless protein.
- Non-specific treatments which are not specifically targeting and neutralizing the toxic oligomers
- Often complicated drug treatments that require expensive hospital care
- Targeting plaque is unlikely to be sufficiently effective and may result in serious side effects





About Alzheimer

In Alzheimer's disease, the nerve cells in the brain are damaged by abnormal protein deposits that mainly consist of amyloid-beta 42 (Aβ42), a type of small protein that also occurs in a healthy brain. When the Aβ42 molecule clumps together, stable accumulations are formed in the brain, plaques, but also so-called oligomers.

Oligomers differ structurally from the plaque and, unlike the plaque, are highly toxic to brain cells. They damage important functions that make the contact surfaces between the nerve cells, the synapses, stop working normally. Synapses are the places in the brain where electrical and chemical signals are transmitted from one nerve cell to another, and their function is critical to our ability to remember, react, think and act. Eventually the nerve cell dies.

The disease first affects the parts of the brain that handle short-term memory, but eventually the disease spreads over the entire brain and the patient finds it increasingly difficult to carry out daily tasks. In the end, the patient cannot manage on their own, but requires care and continuous review.

Alzheimer's is a disease that basically anyone can get, and which is strongly age-dependent. Over 95% of all cases affect those over 65, and in these cases there is not a strong genetic component driving the disease. The disease then increases sharply in prevalence in the 75-80 age range. At age 95, the prevalence is perhaps as high as 50%. As the average life expectancy is increasing, this will entail large patient groups in the near future.

Business model

Alzinova's business model is to bring projects into clinical development with the aim of demonstrating that the drug candidates are safe and well tolerated as well as determining proof-of-concept, i.e. to demonstrate efficacy in patients with Alzheimer's. Based on clinical data, the Company intends to identify one or several strategic partners that can acquire projects for further development and commercialization. This can be done through out-licensing with a partnership where the Company jointly with the partner brings the drug to the market, or through a complete acquisition of the drug candidate for further development.

Out-licensing

A common option for development companies like Alzinova is to out-license projects to one or more global pharmaceutical companies. Companies can either have exclusivity in a limited market and you agree with several partners to cover the market globally, or you have a global partner who takes the drug to the entire market. A typical arrangement for out-licensing is initial compensation and then future instalments linked to pre-defined milestones during further development, the regulatory process and commercialization with high revenues linked to future drug sales.

The Company has so far taken several important steps towards out-licensing and commercialization. The data shows "best-in-class" potential, which is very attractive for partnering. Furthermore, Alzinova has secured a scalable manufacturing process for ALZ-101, which facilitates the Company moving to phase 2 so that a partner can quickly start. With positive results in the Company's pharmaceutical projects ALZ-101 and ALZ-201, there are several options. One is to out-license the vaccine ALZ-101 when the phase 1b study is complete, and another option is to take it through phase 2 and then out-license it to a partner. For the antibody ALZ-201, this could be out-licensed already during the preclinical phase, alternatively after phase 1b studies. The Company's focus going forward is precisely on business development with several active ongoing dialogues in parallel with clinical development of the project portfolio.

Market

Every year, around 10 million people globally fall victim to dementia; Alzheimer's disease accounts for approximately 60-70 percent of that number. The incurable dementia disorders represent a growing problem as life expectancy increases. It is estimated that dementia afflicts around 55 million patients worldwide The number is projected to rise to more than 130 million people in 2050. It is estimated that more than 30 million people around the world are suffering from Alzheimer's disease today, and the number is set to triple by 2050[1].

The cost to society of the disease is estimated today to be approximately USD 1.3 trillion annually. The annual pharmaceutical expenditure related to just symptom-relief drugs for Alzheimer's disease amounts to approximately USD 6 billion. Although the first drug for disease modification was recently approved in the USA, there is still a very long way to go to fully treat and prevent the progression of Alzheimer's disease.

The sales and revenue potential of a new effective drug is therefore substantial even if it only obtains an initially limited market share. The reason that the initial estimated sales revenues are relatively low compared to other therapeutic areas is that there are currently no good medical alternatives. If effective treatment alternatives were to come to the market, for example Alzinova's pharmaceuticals, the Company estimates that annual sales could multiply. According to Global Data, the annual sales volume of disease modifying therapies for Alzheimer's disease in the major markets US, Germany, France, UK, Italy, Spain, Japan, China and India will amount to USD 13 billion in 2028.

[1] World Health Organization (WHO) – Alzheimer's facts, september 2021.

Investment highlights

- Alzinova's goal is to enable Alzheimer's patients to live an independent and active life.
- Alzinova's lead candidate, ALZ-101, is a therapeutic vaccine against Alzheimer's disease. The vaccine is in clinical development with a phase 1b study in Alzheimer's patients.
- Based on the same technology, Alzinova is also developing a monoclonal antibody, ALZ-201, as a complementary treatment to fight Alzheimer's disease.
- The data show that the unique specificity of Alzinova's vaccine (ALZ-101) and the monoclonal antibody (ALZ-201) provides "best-in-class" potential.
- Preparatory activities are underway for the next clinical development phase, making Alzinova's candidates more attractive for strategic partnership.

Every 5 seconds someone is affected by Alzheimer's disease

Financial information

Corporate structure and shareholding

Alzinova has no subsidiaries and is not part of any group. Neither does the Company hold any shares.

Financial development

During the period October-December, the Company has continued to invest in the further development of ALZ-101, which is now in clinical phase 1b. The Company has also initiated development for clinical trials of the antibody ALZ-201, with the aim of treating and also preventing the progression of Alzheimer's disease.

The Company's total expenses for the period amounted to SEK 8.1 million, an increase of approximately SEK 2.1 million compared to the previous quarter. The majority of the increase in costs, approximately SEK 1.7 million, relates to higher research and development costs and, in particular, planned costs for the ongoing clinical trial, which is now fully recruited. The majority of the research and development costs have been capitalised on the balance sheet. Personnel costs increased by approximately SEK 0.4 million compared to the previous quarter, attributable to strengthening of the organisation and bonus programmes.

Cash flow from operating activities during the period amounted to SEK -3.4 million (SEK -2.8 million in the previous year's period), and expenditure on ongoing capitalised research and development costs amounted to SEK -3.4 million (SEK -2.7 million in the previous year's period). Total cash flow amounted to SEK -6.8 million (SEK -5.5 million in the previous year's period).

At the end of the period (2022-12-31), the Company's equity amounted to approximately SEK 106 million with an equity ratio of 94.5% (SEK 88 million and 96.5% respectively at 2021-12-31), and total cash balance amounted to approximately SEK 32 million (SEK 29 million at 2021-12-31).

The Company's TO3 warrants, which expire in April 2023, may provide the Company with an additional capital injection of up to approximately SEK 40.8 million before costs. Work is ongoing on various financing options, and although the TO3 warrants will provide a lower capital injection, the Board still believes that there is a good chance of obtaining the necessary financing to ensure the continuation of planned operations over the next 12 months. The Company also has the ability to reprioritise activities based on the capital available in the Company, which is why the Board believes that the conditions for continued operation are met.

Risk factors

Alzinova maintains procedures to continuously identify and manage risk factors. A detailed assessment of the Company's uncertainty factors was included in the Annual Report 2021, as well as in the Prospectus for Alzinova Rights Issue 2022.

Auditor's review

This report has not been reviewed by the Company's auditors.

Policies for the preparation of the interim financial report

The interim financial report is prepared in accordance with the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3).

The Board of Directors and the Chief Executive Officer hereby confirm that this interim report provides a true and fair view of the Company's operations, financial position and earnings, and describes significant risks and uncertain factors the Company is facing.

Mölndal, February 23, 2023
Alzinova AB

Income statement

SEK	Oct-Dec 2022 3 months	Oct-Dec 2021 3 months	Jan-Dec 2022 12 months	Jan -Dec 2021 12 months
Net sales	-	-	-	-
Own work capitalized	3,402,487	2,722,956	16,633,432	17,321,738
	3,402,487	**2,722,956**	**16,633,432**	**17,321,738**
Operating expenses				
Other external expenses	-6,149,121	-2,878,135	-23,032,905	-19,025,906
Personnel expenses	-2,001,165	-2,292,311	-6,686,880	-5,815,184
Operating result	**-4,747,799**	**-2,447,490**	**-13,086,353**	**-7,519,352**
Result from financial items				
Interest income	17,905	-	17,905	-
Interest expenses	-4,913	-8,134	-19,401	-32,654
Result after financial items	**-4,734,807**	**-2,455,624**	**-13,087,849**	**-7,552,006**
Result before tax	**-4,734,807**	**-2,455,624**	**-13,087,849**	**-7,552,006**
Result for the period	**-4,734,807**	**-2,455,624**	**-13,087,849**	**-7,552,006**

Balance sheet

SEK	31 December 2022	31 December 2021
ASSETS		
Fixed assets		
Intangible assets		
Capitalized expenditure for development work	76,648,660	60,015,227
Patent	1,632,086	1,632,086
	78,280,746	**61,647,313**
Total fixed assets	**78,280,746**	**61,647,313**
Current assets		
Short term receivables		
Tax receivables	205,684	129,296
Other receivables	630,186	575,385
Prepaid expenses and accrued income	466,784	503,861
	1,302,654	**1,208,542**
Cash and cash receivables	**32,037,675**	**28,835,537**
Total current assets	**33,340,329**	**30,044,079**
TOTAL ASSETS	**111,621,075**	**91,691,392**
EQUITY AND LIABILITIES		
Equity		
Restricted equity		
Share capital	8,526,206	4,149,015
Fund for development costs	74,585,545	57,946,386
	83,111,751	**62,095,401**
Unrestricted equity		
Share premium	144,644,792	118,872,676
Retained result	-109,135,477	-84,944,312
Results for the year/period	-13,087,849	-7,552,006
	22,421,466	**26,376,358**
Total equity	**105,533,217**	**88,471,759**
Long term liabilities		
Other long term liabilities	800,000	800,000
	800,000	**800,000**
Short term liabilities		
Accounts payable	3,170,435	792,374
Other current liabilities	722,782	570,137
Accrued expenses and prepaid income	1,394,641	1,057,122
	5,287,858	**2,419,633**
TOTAL EQUITY AND LIABILITIES	**111,621,075**	**91,691,392**

Change in equity, condensed

Jan - Dec 2022 12 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the year	**4,149,015**	**57,946,386**	**118,872,676**	**-92,496,318**	**88,471,759**
Rights issue	4,377,191		32,482,459		36,859,650
Transaction cost rights issue			-6,710,343		-6,710,343
Transfer within capital		16,639,159		-16,639,159	0
Net result for the period				-13,087,849	-13,087,849
At the end of the period	**8,526,206**	**74,585,545**	**144,644,792**	**-122,223,326**	**105,533,217**

Jan - Dec 2021 12 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the year	**4,149,015**	**40,624,648**	**118,872,676**	**-67,622,574**	**96,023,765**
Transfer within capital		17,321,738		-17,321,738	0
Net result for the period				-7,552,006	-7,552,006
At the end of the period	**4,149,015**	**57,946,386**	**118,872,676**	**-92,496,318**	**88,471,759**

Cash flow statement, condensed

SEK	Oct - Dec 2022 3 months	Oct - Dec 2021 3 months	Jan - Dec 2022 12 months	Jan - Dec 2021 12 months
Operating activities				
Result after financial items	-4,734,807	-2,455,624	-13,087,849	-7,552,006
Adjustments for items not included in cash flow	-	-	-	-
Cash flow from operating activities before change in working capital	**-4,734,807**	**-2,455,624**	**-13,087,849**	**-7,552,006**
Cash flow from change in working capital				
Increase (-)/Decrease (+) in operating receivables	-99,057	-358,300	-94,112	-695,499
Increase (+)/Decrease (-) in operating liabilities	1,397,166	31,824	2,868,225	-1,572,261
Cash flow from operating activities	**-3,436,698**	**-2,782,100**	**-10,313,736**	**-9,819,766**
Investing activities				
Acquisition of intangible fixed assets	-3,402,487	-2,722,955	-16,633,433	-17,321,738
Cash flow from investing activities	**-3,402,487**	**-2,722,955**	**-16,633,433**	**-17,321,738**
Financing activities				
Share issue	-	-	36,859,650	-
Transaction costs share issue	-	-	-6,710,343	-
Cash flow from financing activities	**0**	**0**	**30,149,307**	**0**
Cash flow for the period	**-6,839,185**	**-5,505,055**	**3,202,138**	**-27,141,504**
Cash and cash equivalents at the beginning of the period	**38,876,860**	**34,340,592**	**28,835,537**	**55,977,041**
Cash and cash equivalents at the end of the period	**32,037,675**	**28,835,537**	**32,037,675**	**28,835,537**

The share

Alzinova's share was listed on the Spotlight Stock Market on November 25, 2015. As of March 11, 2019, the Company is listed on the Nasdaq First North Growth Market in Stockholm. There is one class of shares in the Company. The share entitles to one (1) vote per share. Each share carries an equal right to a share in the Company's assets and results. As of December 31, the number of shares in Alzinova amounted to 32,419,034.

Share-based incentive programs

The Company's CEO and other senior executives as well as parts of the board, through a long-term incentive program, hold a total of 159,165 warrants of series 2020/2023, which entitle them to subscribe for an equal number of shares during the period June 1 - July 31, 2023.

If the warrants are fully exercised, this corresponded at the time of issue, a dilution of the number of shares and votes in the Company of approximately 2%, and after rights issue carried out during the current year, it corresponds to a dilution of approximately 0.5%.

Rights issue

In 2020, the Company carried out a rights issue together with a directed issue of warrants of series TO2 2020/2022. A total of 867,590 warrants were exercised during January - February 2022, increasing the number of shares in the Company by 443,795 shares and raising approximately SEK 2.8 million in capital before issue costs. For more information, please refer to the interim report January - March 2022.

During the period April - June 2022, the Company carried out a rights issue with attached warrants of series TO3. The issue increased the number of shares in the Company by 16,209,515 shares and raised approximately SEK 34.0 million for the Company before issue costs. For existing shareholders who did not participate in the rights issue, the dilution amounted to approximately 50%.

Upon full exercise of the Series TO3 warrants expiring in April 2023, the Company's shares may increase by an additional 12,967,612 shares, representing a dilution of approximately 28% of the total number of shares in the Company, and provide an additional capital contribution of up to approximately SEK 40.8 million before costs. For more information, please read the interim report April - June 2022.

Largest owners per December 30, 2022

Shareholder	No. of shares	Capital %
Maida Vale Capital AB	3,808,226	11.75%
Försäkrings AB Avanza Pension	2,600,038	8.02%
Nordnet Pensionsförsäkring AB	1,176,147	3.63%
Sara Gjertz	898,553	2.77%
MIVAC Development AB	761,787	2.35%
Ålandsbanken, for owner	709,120	2.19%
Patrik Ahlvin	704,000	2.17%
UBS Switzerland AG	470,540	1.45%
Moll Invest AB	415,440	1.28%
Ola Hermansson, with companies	400,000	1.23%
Total 10 largest shareholders	**11,943,851**	**36.84%**
Total other shareholders	20,475,183	63.16%
Total all shareholders	**32,419,034**	**100.00**

Financial calendar

2023

Annual report 2022	2023-04-28
Interim report 1, 2023	2023-05-17
Annual general meeting 2023	2023-05-30
Interim report 2, 2023	2023-08-24
Interim report 3, 2023	2023-11-02
Year-end report, 2023	2024-02-28

Financial reports are available on the Company's website www.alzinova.com as of the date of publication.

For further information, please contact:

Kristina Torfgård, CEO, kristina.torfgard@alzinova.com, telephone +46 708 467975
Håkan Skogström, CFO, hakan.skogstrom@alzinova.com, telephone +46 705 850859
or mail directly to info@alzinova.com

Glossary, definitions and abbreviations

Aβ42 - amyloid-beta 42	A peptide (part of a protein) produced by the body that can aggregate in the brain and cause Alzheimer's disease
Clinical studies	A study evaluating a medicine, conducted in humans
CTAD	Clinical Trials in Alzheimer's Disease conference
Disease-modifying treatment	Treatment that targets the underlying cause of the disease
Monoclonal antibody	A type of antibody produced by a single clone of cells
Neurotoxic	Dangerous or poisonous to the brain
Oligomers	Proteins or peptides, clumped together, used to designate soluble peptide clumps
Peptide	Part of a protein (a small chain of amino acids too small to be classified)
Plaque	Local accumulation of clumped insoluble protein, in Alzheimer's mainly consisting of the peptide Abeta42

alzinova

We will make it possible for Alzheimer's patients to live an independent and active life

Alzinova AB (publ)
AstraZeneca BioVentureHub
Pepparedsleden 1
SE-431 83 Mölndal
Sweden